Background and Purpose-The ability of middle cerebral arteries (MCAs) to utilize intracellular smooth muscle (SM) Ca 2ϩ to produce constriction in response to pressure and agonists was assessed in relation to hemorrhagic stroke development in Wistar-Kyoto stroke-prone (SHRSP) and stroke-resistant (srSHR) spontaneously hypertensive rats. Methods-MCAs were studied with the use of a pressure myograph at 100 mm Hg. 
C erebrovascular pressure-dependent constriction plays an important role in promoting cerebral blood flow autoregulation. 1, 2 Pressure-dependent constriction in the middle cerebral arteries (MCAs) and cerebral blood flow autoregulation in the cerebrum of Wistar-Kyoto stroke-prone spontaneously hypertensive rats (SHRSP) become defective before and after hemorrhagic stroke development. [3] [4] [5] The loss of cerebral blood flow autoregulation in SHRSP before stroke could promote overperfusion of the brain under hypertensive conditions.
The role of intracellular smooth muscle (SM) Ca 2ϩ in promoting pressure-dependent constriction remains controversial. 2 Stretched cultured vascular SM cells and the SM of stretched aortic rings produce inositol triphosphate (IP 3 ), 6, 7 which can activate the release of sarcoplasmic Ca 2ϩ . Pressurization of dog renal arteries produces an increase in SM IP 3 and diacylglycerol (DAG) levels. 8 Fura-2 studies of isolated coronary arterial SM 9 and pharmacological studies of cerebral arteries 10, 11 indicate that stretch produces an intracellular release of Ca 2ϩ and phasic constriction in the absence of extracellular Ca 2ϩ . These responses are inhibited by phospholipase C (PLC) inhibitors and ryanodine, which depletes intracellular SM Ca 2ϩ stores. 10, 11 PLC inhibition has also been shown to inhibit pressure-dependent constriction in rat cerebral arteries. 12 Drugs such as thapsigargin and cyclopiazonic acid (CPA), which deplete SM sarcoplasmic stores of Ca 2ϩ as well as the PLC inhibitor U-73122, inhibit pressuredependent constriction in rat renal arterioles. 13 These studies suggest that in some arterial systems, pressure-dependent constriction may involve the utilization of an internal SM store of Ca 2ϩ . In the present study I tested the hypothesis that the MCAs of SHRSP and stroke-resistant spontaneously hypertensive rats (srSHR) utilized an internal SM store of Ca 2ϩ to mediate pressure-dependent constriction and assessed the possibility that an altered ability to utilize this store after stroke development might be responsible in promoting the alterations in pressure-dependent constriction observed in the MCAs of SHRSP after hemorrhagic stroke development.
Materials and Methods
Experiments using SHRSP and srSHR were in compliance with the guidelines of the Canadian Council on Animal Care. At weaning (5 weeks of age), the rats were fed a Japanese-style diet (Zeigler Bros) containing 4% NaCl. SHRSP fed the diet develop hemorrhagic stroke at approximately 12 weeks of age and experience 100% mortality by 18 weeks of age, while srSHR fed the same diet do not develop stroke. 14 The relationship of stroke development to blood pressure (BP) and the behavioral characteristics of stroke in SHRSP have been described elsewhere. 3, 14 Before sampling, the systolic BPs of unanesthetized rats were measured by a tail cuff compression method. Details of the BP measuring and arterial pressure myograph techniques have been described previously. [3] [4] [5] 14 Rats anesthetized with 65 mg/kg IP sodium pentobarbital were exsanguinated, and the brain was removed and placed in oxygenated (95% O 2 /5% CO 2 ) Krebs' physiological salt solution cooled with ice. A segment of the right or left MCA that crosses over the rhinalis fissure was excised and mounted in a pressure myograph. [3] [4] [5] The distal end and the side branches of the artery were tied to form a closed artery filled with Krebs' solution, and the exterior of the artery was suffused with oxygenated Krebs' solution at 37 C. Through the use of a pressurized reservoir and reduction valves, any desired back pressure could be applied instantly to the arterial lumen. Arterial lumen changes were viewed with a microscope, video recorded, and measured at a magnification of ϫ322.
After the experiment, the brain was fixed in PO 4 (85 mmol/L)-buffered 4% formaldehyde and 1% glutaraldehyde solution (pH 7.4), cut into 0.5-mm sections, and studied with a microscope to confirm the presence of intracerebral hemorrhage.
Pressure-dependent constriction in the MCAs was studied by a previously outlined protocol. [3] [4] [5] Initially, the MCAs were pressurized to 100 mm Hg for 30 minutes, permitting the MCAs to develop pressure-dependent constriction. Subsequently, the pressure was decreased to 0 mm Hg for 6 minutes. The MCAs were then repressurized to 100 mm Hg, and the change in lumen diameter was measured from 1 second to 4 minutes after pressurization. The lumen diameter present at 1 second after pressurization to 100 mm Hg represents the diameter present before the engagement of pressuredependent constriction. The MCA will constrict to a new steady state lumen diameter appropriate to the applied pressure within 3.5 minutes. The reduction in lumen diameter between 1 second and 4 minutes after pressurization to 100 mm Hg was used as a measure of pressure-dependent constriction.
All the pharmacological manipulations outlined in this report were performed on arteries at a pressure of 100 mm Hg. The chemicals used were purchased from Sigma Chemical Co.
The n values within the figures represent the number of rats sampled. MeanϮ1 SE values are shown. Results were considered significantly different at PϽ0.05. An ANOVA determined whether significant between-group differences existed in a given parameter, and an unpaired Student's t test (compensated for multiple comparisons with the Bonferroni method) was used to determine subgroup differences. Linear regression analysis and Pearson product correlations were used to determine whether relationships existed between 2 parameters.
Results
The mean age of the rats was 14.2Ϯ0.5 weeks. Poststroke SHRSP had higher (PϽ0.05) mean systolic BPs (245Ϯ18 mm Hg) than either srSHR (213Ϯ14 mm Hg) or prestroke SHRSP (219Ϯ12 mm Hg).
The Table outlines the characteristics of pressuredependent constriction observed in the MCAs of SHR. The MCA lumen diameters present 1 second after pressurization to 100 mm Hg after equilibration to 0 mm Hg were not different between prestroke SHRSP and srSHR, while MCAs from poststroke SHRSP had smaller lumen diameters than the latter groups. The MCAs of prestroke SHRSP and srSHR constricted in response to a pressure step of 100 mm Hg, whereas the MCAs of poststroke SHRSP did not. After 4 minutes of equilibration to 100 mm Hg, the MCAs of srSHR and prestroke SHRSP produced greater amplitudes of constriction and maintained a smaller lumen diameter than those of prestroke or poststroke SHRSP. The addition of 1 mol/L nifedipine into normal Krebs' solution or the presence of Ca 2ϩ -free/EGTA Krebs' solution maximally relaxed the MCA. Under the latter conditions, pressure-dependent constriction was inhibited, and the MCA could not elicit any constriction in response to a pressure step of 100 mm Hg. Pressurization to 100 mm Hg for 1 second after equilibration to 0 mm Hg did not produce dilation of the lumen in the MCAs of poststroke SHRSP, indicating that these MCAs had basal tone, previously described as non-pressure-dependent tone, 3,5 that was not modified by a decrease in pressure. Both pressure-dependent constriction and non-pressure-dependent tone were inhibited by 1 mol/L nifedipine. nifedipine or in the absence of external Ca 2ϩ , while those of poststroke SHRSP failed to respond to the agonists ( Figure  1A and 1B). The amplitude of constriction observed in the MCAs of srSHR in response to each agonist was comparable or greater than that present in the MCAs of prestroke SHRSP.
The response observed in the MCAs of poststroke SHRSP was not different from zero.
Vasopressin and serotonin constriction of the MCA in the presence of nifedipine or in Ca 2ϩ -free/EGTA Krebs' solution was likely mediated by a release of Ca 2ϩ from an intracellular SM store. Therefore, the aforementioned results would predict that either the size of the internal Ca 2ϩ pool used for contraction was reduced or absent or that the signal transduction mechanisms promoting the release of Ca 2ϩ from the pool in response to the agonists were defective in the MCAs of poststroke SHRSP. Alterations in contractile sensitivity to Ca 2ϩ may also have played a role in inhibiting constriction (see Discussion).
Constriction in response to 100 mmol/L [K ϩ ] o in the MCAs was inhibited by 1 mol/L nifedipine and did not occur in Ca 2ϩ -free/EGTA Krebs' solution, indicating that this response depended on the presence of external Ca 2ϩ influx through SM L-type Ca 2ϩ channels. In normal Krebs' solution (2.5 mmol/L Ca 2ϩ ) lacking nifedipine, the response in prestroke SHRSP was not different from that measured in srSHR, while the MCAs of poststroke SHRSP were unresponsive to 100 mmol/L [K ϩ ] o ( Figure 1C ). Both vasopressin and serotonin utilized identical pools of internal Ca 2ϩ for constriction ( Figure 2 ). The MCAs of srSHR produced a phasic constrictor response to vasopressin in Ca 2ϩ -free/EGTA Krebs' solution, indicating that the internal SM Ca 2ϩ had been released and chelated by extracellular EGTA. The subsequent addition of serotonin failed to produce constriction, indicating that constriction to serotonin was promoted through the release of the same internal Ca 2ϩ pool activated by vasopressin.
In addition to releasing internal SM Ca 2ϩ , both serotonin and vasopressin opened L-type Ca 2ϩ channels. As shown in Figure 3 , despite the inability to elicit constriction in response to elevated [K ϩ ] o or to utilize an internal Ca 2ϩ store for constriction (ie, to constrict in the presence of Ca 2ϩ -free/ An attempt was made to deplete the internal SM Ca 2ϩ pool released by vasopressin and serotonin and prevent its refilling by the use of a sarcoplasmic Ca 2ϩ pump inhibitor, CPA. The ability of the MCA to elicit pressure-dependent constriction under the latter conditions was tested in srSHR. As shown in Figure 4 , the experiment was started under conditions in which both the lumen and exterior of the MCAs of srSHR were bathed with Ca 2ϩ -free/EGTA Krebs' solution. The arteries dilated maximally and did not constrict in response to a pressure step of 100 mm Hg. Then 2.5 mmol/L [Ca 2ϩ ] o was introduced into the suffusate, and pressure-dependent constriction to a pressure step of 100 mm Hg indicated a 44% constriction. The MCAs, now pressurized to 100 mm Hg, were resuffused with Ca 2ϩ -free/EGTA Krebs' solution. Pressure-dependent constriction disappeared in the arteries. In the absence of external Ca 2ϩ , vasopressin was introduced into the bath and produced a potent phasic constriction of the MCA (see vasopressin peak 2. in Figure 4 ). After 10 minutes, the constrictor response to vasopressin disappeared, and the arteries dilated maximally. The subsequent introduction of 2.7 mol/L serotonin failed to promote constriction, suggesting that the Ca 2ϩ from the common internal SM pool released by serotonin and vasopressin was depleted from the arteries. The arteries were then flushed with Ca 2ϩ -free/EGTA Krebs' solution containing CPA (10 mol/L) for 4 minutes and Krebs' solution containing 2.5 mmol/L [Ca 2ϩ ] o plus CPA for another 6 minutes. CPA inhibits the uptake of Ca 2ϩ into the sarcoplasmic reticulum of arteries. The ability of the MCA to constrict to a pressure step of 100 mm Hg in the presence of CPA was tested (see 5. in Figure 4 ). Under conditions in which the sarcoplasmic Ca 2ϩ should have been depleted and prevented from refilling, the MCAs of srSHR still exhibited approximately 24% constriction to the pressure step. However, the pressure-dependent constriction response was significantly less than the 44% pressure-dependent constriction observed before the applied treatment. An analysis of the absolute lumen diameter changes occurring at A and B of Figure 4 indicated that the reduction in the amplitude of pressure-dependent constriction that occurred under conditions in which the internal Ca 2ϩ store was depleted was achieved by the presence of elevated vascular tone 1 second after 100 mm Hg pressure was applied to the arteries and by a decreased ability to achieve the same reduction in lumen diameter 4 minutes after the application of the pressure step.
In the last phase of the experiment, the ability of the MCAs to constrict to 100 mmol/L [K ϩ ] o in the presence of CPA was tested. In some experiments (3 of 10), CPA totally abolished pressure-dependent constriction. However, such MCAs also failed to constrict to 100 mmol/L [K ϩ ] o , indicating that functional changes other than the depletion of the sarcoplas- ] o was introduced into the suffusate, and the amplitude of constriction in response to a pressure step of 100 mm Hg was measured (1). The MCAs were then resuffused with Ca 2ϩ -free/EGTA Krebs' solution at 100 mm Hg and constricted with 0.17 mol/L vasopressin. The peak constriction to vasopressin (2) and the degree of constriction over the maximal relaxed state after 10 minutes in the presence of vasopressin (3) are shown. Serotonin (5HT) (2.7 mmol/L) was then introduced into the bath (4) and failed to produce further constriction, suggesting that the common internal Ca 2ϩ pool released by vasopressin and serotonin was depleted. MCAs were further flushed with Ca 2ϩ -free/EGTA Krebs' solution, and the sarcoplasmic reticulum Ca 2ϩ uptake pump inhibitor CPA (10 mol/L) was introduced into the bath to prevent the sarcoplasmic reticulum from reaccumulating Ca 2ϩ . [Ca 2ϩ ] o (2.5 mmol/L) was then added to the bath for 6 minutes, in the presence of CPA and pressure-dependent constriction to a pressure step of 100 mm Hg was subsequently measured (5) . Finally, the ability of the MCAs to constrict in response to 100 mmol/L [K ϩ ] o was tested in the presence of CPA (6) (sample size, 6 MCA/6 srSHR).
mic Ca 2ϩ pool had occurred. In 1 of 10 experiments, the MCAs contracted to pressure (40%) after treatment but did not respond to elevated K ϩ . MCAs that could not constrict to elevated K ϩ after CPA treatment were rejected from the experiment. The remaining arteries (6 MCA/6 srSHR) were used in the experiment outlined in Figure 4 . In the presence of 2.5 mmol/L [Ca 2ϩ ] o , there existed a direct relationship between the ability of the MCA to constrict to pressure after the depletion of the sarcoplasmic SM Ca 2ϩ pool (B in Figure 4 ) and the ability of the MCA to constrict to 100 mmol/L Figure 4 ). These observations suggested that the decrease in pressure-dependent constriction observed before versus after the depletion of the SM sarcoplasmic Ca 2ϩ was not due to the involvement of the Ca 2ϩ stores in promoting pressuredependent constriction but rather was the result of secondary changes in the MCA (ie, the inability to constrict to SM depolarization) associated with CPA treatment. The observation that pressure-dependent constriction cannot take place in the MCAs of srSHR or SHRSP in the presence of nifedipine (when [Ca 2ϩ ] o is 2.5 mmol/L) or in the absence of external Ca 2ϩ , even when internal SM Ca 2ϩ stores are full, further supports the hypothesis that an internal SM Ca 2ϩ source is not used to mediate pressure-dependent constriction.
Discussion
After stroke development, the MCA of SHRSP lost the ability to elicit pressure-dependent constriction and could not utilize an intracellular source of Ca 2ϩ to constrict in response to vasopressin or serotonin. The MCAs of poststroke SHRSP still contracted in response to serotonin and vasopressin, but such constriction took place only in the presence of extracellular Ca 2ϩ and was blocked by nifedipine. This suggested that constriction was maintained by the movement of Ca 2ϩ into the SM through L-type channels.
The signal transduction mechanisms promoting arterial constriction in response to serotonin [15] [16] [17] or vasopressin 18 involve SM PLC activation. This elevates intracellular IP 3 and DAG. IP 3 mediates the release of Ca 2ϩ from an intracellular Ca 2ϩ pool, and, through a signal cascade, DAG activation of protein kinase C (PKC) mediates sensitization of the contractile apparatus to Ca 2ϩ . The inability to utilize internal SM Ca 2ϩ to elicit constriction may be indicative of defects in mechanisms mediating the release of sarcoplasmic Ca 2ϩ or the possible depletion of the internal SM Ca 2ϩ stores. A decrease in SM contractile sensitivity to Ca 2ϩ could also contribute to this dysfunction. Constriction in response to phorbol dibutyrate in the presence of nifedipine (a PKCmediated response) is abolished in the MCAs of poststroke SHRSP. 19 Therefore, the activation of PKC by vasopressin or serotonin (secondary to DAG) might also be attenuated, resulting in the failure of the contractile apparatus to be sensitized to Ca 2ϩ . In such an instance, the increases in 5 and may be the result of a dysfunction in the voltage sensor in the L-type channel. In the MCAs of poststroke SHRSP, the channel behaved as though it was locked in a semi-open state and was unresponsive to alterations in SM membrane potential. 5 If the latter channel was involved in promoting pressure-dependent constriction secondary to pressure-dependent depolarization, the inability of the arteries to constrict to depolarization would inhibit pressure-dependent constriction. Paradoxically, although the MCAs of poststroke SHRSP did not constrict to depolarization, they did constrict to vasopressin and serotonin via Ca 2ϩ entry through L-type channels. This inconsistency may be explained by the observation that a variety of agonists can increase Ca 2ϩ conductance into arterial SM cells through L-type channels when the membrane potential is constant, 20 -22 indicating that the channel can be opened in a voltage-independent manner.
A future challenge will be to link and critically assess the involvement of PLC and PKC in promoting arterial constriction to pressure. Both PLC and PKC inhibitors inhibit pressure-dependent constriction in cerebral arteries. 12, 19 However, paradoxes exist. One would expect that PLC activation in response to elevated pressure might lead to the production of IP 3 , causing the release of sarcoplasmic Ca 2ϩ . However, studies have shown that PLC activation in cerebral arteries can form DAG with no measurable IP 3 . 17 This can occur by PLC cleavage of phosphatidylcholine. 23 It is possible that pressure-dependent constriction in cerebral arteries is mediated by a phospholipase pathway that does not involve the breakdown of phosphatidylinositol and the production of IP 3 but (like the breakdown of phosphatidylcholine) still involves the production of DAG. If such was the case, PKC activation could take place without an IP 3 -mediated release of Ca 2ϩ from an internal SM pool. Other possibilities also exist. Studies have implicated 20-hydroxyeicosatetraenoic acid as an a signaling agent for pressure-dependent constriction in rat cerebral arteries. 1 20-HETE is a cytochrome P-450 metabolite of arachidonic acid that is increased in pressurized cerebral arteries. Preventing the production of 20-HETE or antagonizing its contractile actions with inhibitors prevents pressure-dependent constriction from occurring in cerebral vessels in vitro and inhibits cerebral blood flow autoregulation in vivo. 1 20-HETE is capable of both depolarizing vascular SM (by decreasing K ϩ conductance), thus opening voltage-gated Ca 2ϩ channels, and activating PKC. 1 If the actions of 20-HETE did not involve the production of IP 3 , then this could provide a signal pathway for pressuredependent constriction that involves SM PKC activation, depolarization, and the opening of voltage-gated Ca 2ϩ channels but not the release of Ca 2ϩ from a sarcoplasmic stores.
